2025年ASCO会议上Servier的演讲进一步巩固了该公司在IDH突变癌症领域的领导地位-动脉网

Servier Presentations at ASCO 2025 Reinforce Company Leadership in IDH-Mutated Cancers

CISION 等信源发布 2025-05-23 05:01



可切换为仅中文







BOSTON

波士顿

，

May 22, 2025

2025年5月22日

/PRNewswire/ -- Servier today announced that it will present updates from its research programs at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on

/PRNewswire/ -- 施维雅今日宣布，将在2025年美国临床肿瘤学会（ASCO）年会上展示其研究项目的最新进展。

May 30

5月30日

–

June 3

6月3日

在

Chicago

芝加哥

。

Presentations will span across a range of cancers including chondrosarcoma, cholangiocarcinoma and myelodysplastic syndrome, reinforcing Servier's commitment to the development of precision medicines for isocitrate dehydrogenase (IDH) mutated cancers.

涵盖的癌症范围包括软骨肉瘤、胆管癌和骨髓增生异常综合征，再次印证了施维雅致力于开发针对异柠檬酸脱氢酶 (IDH) 突变癌症的精准药物。

'As industry leaders in IDH-mutated cancers, we look forward to sharing updates regarding the expansion of our clinical development program at this year's ASCO,' said

“作为IDH突变癌症领域的行业领导者，我们期待在今年的ASCO会议上分享我们临床开发项目的扩展更新，”

Becky Martin

贝琪·马丁

, PhD, Chief of Medical at Servier Pharmaceuticals. 'Innovation in precision medicine, including targeted therapies, is critical to improving outcomes for people living with cancer, and we are pleased to share updates on several Phase 3 programs that have the potential to bring new options to patients living with IDH-mutated cancers.' .

博士，施维雅制药的医学总监。 “精准医疗的创新，包括靶向治疗，对改善癌症患者的生活至关重要，我们很高兴分享几个第三阶段项目的新进展，这些项目有可能为IDH突变癌症患者带来新的治疗选择。”

A full list of company-sponsored abstracts to be presented at ASCO can be found

可在ASCO上找到公司赞助的摘要的完整列表

here

这里

。

In addition to its presence at ASCO, Servier will also present research updates at the 30

除了在ASCO的亮相，施维雅还将在第30届

第

European Hematology Association (EHA) Congress on

欧洲血液学协会 (EHA) 大会

June 12-15

6月12日至15日

在

Milan

米兰

。

Media Contact

媒体联系人

Sara Noonan

萨拉·努南

：

sara.noonan@servier.com

I Tel. +1 857 262 3855

我电话：+1 857 262 3855

About Servier in Oncology

关于施维雅在肿瘤学领域

Servier is a global leader in oncology, governed by a non-profit foundation. Servier approaches innovation with a long-term vision, free of influence from fiduciary responsibilities.

施维雅是一家全球领先的肿瘤学公司，由一家非营利基金会管理。施维雅以长远的愿景推动创新，不受信托责任的影响。

Servier is the leader in IDH-mutant targeted therapies and devotes more than 65% of its research and development budget to Oncology. Servier aspires to advance more targeted therapies by identifying mutations and understanding how these mutations impact cancer and its progression. Servier believes we can serve more people by helping the right patients find the right treatment, at the right time..

施维雅是IDH突变靶向治疗的领导者，其超过65%的研发预算用于肿瘤学领域。施维雅致力于通过识别突变并了解这些突变如何影响癌症及其进展，推动更多靶向治疗的发展。施维雅相信，通过帮助合适的患者在合适的时间找到合适的治疗方案，我们可以服务更多的人群。

Servier takes a One Innovation Engine approach to R&D and is actively seeking alliances, partnerships and acquisitions at various stages of the portfolio.

施维雅采取“One Innovation Engine”的方法进行研发，并积极寻求在产品组合的各个阶段建立联盟、合作伙伴关系和收购。

For more information about working with Servier to bring the promise of tomorrow to the patients it serves, visit

欲了解更多关于与Servier合作，为其所服务的患者带来明日希望的信息，请访问

Servier.us

施维雅.us

。

SOURCE Servier Pharmaceuticals

来源：Servier Pharmaceuticals

WANT YOUR COMPANY'S NEWS

想要你公司的新闻吗？

FEATURED ON PRNEWSWIRE.COM?

是否在PRNEWSWIRE.COM上展示？